4.8 Article

Efficient Plasma Cell Differentiation and Trafficking Require Cxcr4 Desensitization

期刊

CELL REPORTS
卷 17, 期 1, 页码 193-205

出版社

CELL PRESS
DOI: 10.1016/j.celrep.2016.08.068

关键词

-

资金

  1. ANR [2010-JCJC-110401, ANR-10-LABX-33, ANR-11-IDEX-0003-01]
  2. Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LabEx LERMIT)
  3. ANR @RAction starting grant [ANR-14-ACHN-0008]
  4. Conseil Regional Midi-Pyrenees
  5. Institut National contre le Cancer (INCa) [PLBIO10-195, INCA-6530]
  6. French Ministry for education
  7. Fondation pour la Recherche Medicale (FRM)
  8. DIM Biotherapies
  9. Societe Francaise d'Hematologie (SFH)
  10. la Ligue Nationale Contre le Cancer
  11. [FP7-MC-IRG-256471]
  12. Agence Nationale de la Recherche (ANR) [ANR-14-ACHN-0008] Funding Source: Agence Nationale de la Recherche (ANR)

向作者/读者索取更多资源

CXCR4 plays a central role in B cell immune response, notably by promoting plasma cell (PC) migration and maintenance in the bone marrow (BM). Gain-of-function mutations in CXCR4 affecting receptor desensitization have been reported in the rare immunodeficiency called WHIM syndrome (WS). Despite lymphopenia, patients mount an immune response but fail to maintain it over time. Using a knockin mouse model phenocopying WS, we showed that, counter-intuitively, a gain of Cxcr4 function inhibited the maintenance of antibody titers after immunization. Although the Cxcr4 mutation intrinsically and locally promoted germinal center response and PC differentiation, antigen-specific PCs were barely detected in the BM, a defect mirrored by early accumulation of immature plasmablasts potentially occupying the survival niches for long-lived PCs. Therefore, fine-tuning of Cxcr4 desensitization is critically required for efficient PC differentiation and maintenance, and absence of such a regulatory process may account for the defective humoral immunity observed in WS patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据